Acquisition Momentum Market consolidation in AI breast imaging creates demand for seamless integration with PACS/RIS and hospital IT ecosystems. With DeepHealth and Volpara acquisitions involving Kheiron entities, position Mia as an adaptable AI layer that complements radiology workflows, supports enterprise data privacy, and can be bundled with cloud or on premise deployments.

Regulatory Readiness European regulatory approval is anticipated, signaling EU health systems ready to adopt AI breast screening. Target EU hospitals, NHS trusts, and radiology groups with regulatory‑ready offerings, pilots to demonstrate clinical value, and clear pathways to reimbursement and adoption.

Strategic Partnerships Strategic partnerships with Atlas Medical, University of Aberdeen, and a Microsoft collaboration demonstrate scalable routes to market. Leverage partner networks for co development, joint marketing, and distribution to radiologists, academic centers, and large health systems; explore OEM or reseller agreements and cloud platform integrations.

ROI Driven Positioning Mia's AI enabled breast screening product offers a compelling ROI narrative through faster readings, enhanced detection, and potential reductions in recalls. Develop pilots with hospitals and imaging centers, provide ROI calculators and outcome data, and align pricing to value delivered within existing imaging workflows and privacy controls.

Licensing and Scale Licensing and strategic collaborations offer a clear path to scale for a small fast growing company. Pursue licensing deals with large hospital networks, insurers, or imaging software platforms, and consider OEM or cloud integration partnerships to accelerate EU and global expansion alongside regulatory momentum.